PT  - JOURNAL ARTICLE
AU  - Umlauft, Maria
AU  - Radojewski, Piotr
AU  - Spanjol, Petar-Marko
AU  - Dumont, Rebecca
AU  - Marincek, Nicolas
AU  - Kollar, Attila
AU  - Brunner, Philippe
AU  - Beyersmann, Jan
AU  - Mueller-Brand, Jan
AU  - Maecke, Helmut
AU  - Laimer, Markus
AU  - Walter, Martin
TI  - Diabetes mellitus and its effects on all-cause mortality after radiopeptide therapy for neuroendocrine tumors
AID  - 10.2967/jnumed.116.180687
DP  - 2016 Sep 01
TA  - Journal of Nuclear Medicine
PG  - jnumed.116.180687
4099  - http://jnm.snmjournals.org/content/early/2016/09/13/jnumed.116.180687.short
4100  - http://jnm.snmjournals.org/content/early/2016/09/13/jnumed.116.180687.full
AB  - We aimed to assess the risk of developing diabetes mellitus and its effects on all-cause mortality after radiopeptide therapy for neuroendocrine tumors (NET). Methods: NET patients received somatostatin radiopeptide therapy with yttrium-90-DOTATOC and/or lutetium-177-DOTATOC. The incidence of diabetes mellitus and its mortality were assessed using univariate and multivariate regression. Results: Overall, 1535 NET patients were enrolled, and received 3807 treatment cycles. After treatment, 72 patients developed diabetes mellitus, including 47 cases after yttrium-90-DOTATOC and 25 cases after combined treatment. The diabetes mellitus risk was higher before than after DOTATOC (Estimate: 0.0032, P < 0.001), and overall survival was similar in patients with and without diabetes mellitus (HR: 1.13, 95%CI: 0.91-1.39, n = 1535, P = 0.27). Conclusion: Radiopeptide therapy does not appear to increase the risk of developing diabetes mellitus in NET patients, while diabetes mellitus does not appear to increase the mortality of NET patients undergoing receptor-targeted radiopeptide therapy.